Raphael Dahmen

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

T. Heise, R. Becker, T. Jax, 2014, Diabetes Care.

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

T. Heise, R. Becker, G. Bolli, 2012, Diabetes Care.

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator

Claudio Cobelli, Roberto Visentin, Chiara Dalla Man, 2016, Diabetes technology & therapeutics.